Thermo Fisher Scientific Inc.
TMO
$532.48
-1.97%
Thermo Fisher Scientific is a global leader in serving science, providing scientific instruments, laboratory equipment, diagnostics consumables, and life science reagents to research, healthcare, and industrial customers. As the largest company in the life sciences tools and diagnostics space, it holds a dominant competitive position with a diversified portfolio spanning analytical technologies, specialty diagnostics, life science solutions, and lab products/services including CRO. The current investor narrative centers on the company's ability to sustain mid-single-digit organic growth amid a post-pandemic normalization, with attention on margin expansion from operational efficiencies and the potential for M&A to drive further scale, while recent geopolitical tensions have introduced modest inflation risk.…
TMO
Thermo Fisher Scientific Inc.
$532.48
TMO 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Thermo Fisher Scientific Inc.'s 12-month outlook, with a consensus price target around $591.27 and implied upside of +11.0% versus the current price.
Average Target
$591.27
0 analysts
Implied Upside
+11.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$490 - $750
Analyst target range
The stock is covered by 26 analysts, with a consensus recommendation of 'Buy' (mean recommendation of 1.61 on a 1-5 scale where 1 is Strong Buy). The average target price is $591.27, implying approximately 10.5% upside from the current price of $535.29. The distribution leans bullish, with no sell ratings and a majority of buy/outperform ratings. The target range spans from a low of $490.00 to a high of $750.00, indicating a wide dispersion of views. The high target of $750.00 assumes significant multiple expansion or accelerated growth, potentially driven by M&A synergies or a stronger-than-expected recovery in life sciences spending. The low target of $490.00 reflects risks such as margin compression, slower organic growth, or adverse currency effects. Recent institutional ratings show a mix of reaffirmations and one downgrade (HSBC from Buy to Hold in June 2026), but overall sentiment remains positive. The wide spread between low and high targets ($260) signals elevated uncertainty, but the consensus still points to upside.
Drowning in data?
Find the real signal!
Bulls vs Bears: TMO Investment Factors
Thermo Fisher presents a balanced risk/reward profile. The bull case is supported by accelerating revenue growth (6.18% YoY), strong free cash flow ($6.748B TTM), and a consensus Buy rating with 10.5% upside to the average target. However, the bear case highlights a premium valuation (32.6x trailing PE vs. industry 25x), aggressive growth expectations (forward PE implies 66% EPS growth), and recent downgrades/inflation headwinds. The single most important tension is whether the company can sustain mid-single-digit organic growth and margin expansion to justify its premium multiple. If growth accelerates further or margins expand, the stock could re-rate toward the high target of $750; if growth disappoints or multiples contract, downside to the low target of $490 is possible. Currently, the evidence slightly favors the bull case given the strong recent momentum and analyst support, but the premium valuation warrants caution.
Bullish
- Strong Revenue Growth Acceleration: Q1 2026 revenue grew 6.18% YoY to $11.005B, accelerating from 5.5% in Q4 2025, signaling a post-pandemic recovery in life sciences spending and operational momentum.
- Healthy Margin Expansion Potential: Operating margin improved to 16.93% in Q1 2026 from 17.75% a year ago, while net margin held at 15.0%, demonstrating cost discipline and scale benefits.
- Robust Free Cash Flow Generation: Trailing twelve-month free cash flow stands at $6.748B, providing ample flexibility for M&A, dividends, and share buybacks, with a FCF yield of ~3.1%.
- Analyst Consensus Bullish with Upside: 26 analysts rate the stock a Buy (mean 1.61/5), with an average target of $591.27 implying 10.5% upside from $535.29, and a high target of $750 suggesting 40% potential.
Bearish
- Premium Valuation vs. Peers: Trailing PE of 32.6x is 30% above the industry average of ~25x, leaving little room for error if growth disappoints or multiples contract.
- Aggressive Forward Earnings Expectations: Forward PE of 19.6x implies ~66% EPS growth, which is aggressive and may be vulnerable to downward revisions if organic growth slows or margins compress.
- Recent Downgrade and Inflation Risk: HSBC downgraded the stock to Hold in June 2026, and management flagged modest inflation risk from Middle East tensions, which could pressure margins.
- Significant Drawdown and Recovery Uncertainty: The stock fell 31.45% from its 52-week high of $643.99 to a low of $403.36, and while it has recovered to $535.29, it remains 17% below the peak, indicating lingering uncertainty.
TMO Technical Analysis
The stock is in a recovery phase after a significant downtrend, with the 1-year price change of +28.06% masking a sharp decline from its 52-week high of $643.99 to a low of $403.36. Currently trading at $535.29, the stock sits at approximately 57% of its 52-week range, suggesting it has rebounded from the lows but remains well below the peak, indicating a potential value opportunity if the recovery continues. The 1-year relative strength of +7.14% versus SPY shows slight outperformance, but the 6-month relative strength of -22.61% highlights the prior weakness. Short-term momentum has turned decisively positive, with the 1-month price change of +12.99% sharply contrasting with the 6-month change of -13.48%. This divergence suggests a potential trend reversal, as the stock has broken its multi-month downtrend and is now building upside momentum. The 1-month relative strength of +12.40% versus SPY confirms strong recent outperformance, though the 3-month relative strength remains negative at -2.55%, indicating the recovery is still nascent. The 52-week low of $403.36 provides a clear support level, while resistance sits at the 52-week high of $643.99. A breakout above $643.99 would signal a resumption of the long-term uptrend, while a breakdown below $403.36 would indicate further downside risk. With a beta of 0.87, the stock is slightly less volatile than the overall market, offering a degree of downside protection during broad selloffs.
Beta
0.87
0.87x market volatility
Max Drawdown
-31.4%
Largest decline past year
52-Week Range
$403-$644
Price range past year
Annual Return
+25.3%
Cumulative gain past year
| Period | TMO Return | S&P 500 |
|---|---|---|
| 1m | +15.3% | +0.3% |
| 3m | +1.1% | +4.7% |
| 6m | -13.9% | +7.5% |
| 1y | +25.3% | +18.4% |
| ytd | -10.1% | +9.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
TMO Fundamental Analysis
Revenue has shown steady growth, with the most recent quarter (Q1 2026) reporting $11.005 billion, up 6.18% year-over-year from $10.364 billion in Q1 2025. This marks an acceleration from the prior quarter's 5.5% growth (Q4 2025: $12.215 billion vs. $11.395 billion in Q4 2024), indicating a positive trajectory. The revenue segments show a balanced mix: Consumables at $4.722 billion, Instruments at $1.555 billion, and Service at $4.728 billion, with the service and consumables lines providing recurring revenue stability. The company is profitable, with net income of $1.651 billion in Q1 2026, up from $1.507 billion in Q1 2025, reflecting a 9.6% increase. Gross margin improved to 40.67% from 40.96% in the prior year quarter, while operating margin expanded to 16.93% from 17.75%, indicating solid cost control. Net margin of 15.00% is healthy and consistent with the company's historical performance, though slightly below the 16.17% in Q4 2025. The balance sheet is strong, with a debt-to-equity ratio of 0.76 and a current ratio of 1.89, indicating ample liquidity. Free cash flow for the trailing twelve months is $6.748 billion, providing significant financial flexibility. The company generated $1.192 billion in operating cash flow in Q1 2026, though capital expenditures of $376 million and a large acquisition outlay of $8.872 billion led to negative free cash flow for the quarter. However, the overall FCF yield of approximately 3.1% (based on market cap of $217.9 billion) is reasonable, and the ROE of 12.61% demonstrates efficient capital use.
Quarterly Revenue
$11.0B
2026-03
Revenue YoY Growth
+6.2%
YoY Comparison
Gross Margin
40.7%
Latest Quarter
Free Cash Flow
$6.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is TMO Overvalued?
Since net income is positive, the PE ratio is the primary valuation metric. The trailing PE stands at 32.61x, while the forward PE is 19.64x, implying the market expects significant earnings growth. The gap between trailing and forward PE suggests a forward earnings growth rate of roughly 66%, which is aggressive but supported by analyst estimates of $37.72 EPS for the current fiscal year. Compared to the industry (Medical - Diagnostics & Research), the stock trades at a premium: the trailing PE of 32.61x is above the sector average of approximately 25x (based on industry data), representing a 30% premium. This premium is partially justified by Thermo Fisher's market leadership, diversified revenue streams, and consistent margin expansion, but it also reflects the market's high growth expectations. Historically, the stock's trailing PE has ranged from roughly 26x to 43x over the past five years. The current 32.61x is near the middle of this range, suggesting it is not excessively overvalued relative to its own history. However, the forward PE of 19.64x is near the lower end of historical forward multiples, indicating that the market may be pricing in a more normalized growth trajectory after the pandemic-era boom.
PE
32.6x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 24x~43x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
21.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Thermo Fisher carries a debt-to-equity ratio of 0.76, which is manageable but not negligible. The company's net margin of 15.0% is healthy but slightly below the prior quarter's 16.17%, indicating potential margin pressure. Operating cash flow of $1.192B in Q1 2026 was offset by $376M in capex and a large $8.872B acquisition outlay, leading to negative free cash flow for the quarter. Revenue concentration is moderate, with the largest segment (Lab Products & Services) accounting for ~49% of sales, but the diversified portfolio mitigates single-product risk. Earnings volatility is low given the recurring revenue from consumables and services, but the post-pandemic normalization could slow growth.
Market & Competitive Risks: The stock's trailing PE of 32.6x represents a 30% premium to the industry average of ~25x, making it vulnerable to valuation compression if growth decelerates. With a beta of 0.87, the stock is less volatile than the market, but it is still sensitive to macro factors such as interest rates and geopolitical tensions. The recent HSBC downgrade to Hold and management's mention of 'modest inflation risk' from Middle East tensions highlight emerging headwinds. Competitive disruption is a risk, though Thermo Fisher's scale and diversified portfolio provide a moat. Sector rotation away from growth stocks could also pressure the multiple.
Worst-Case Scenario: In a severe downturn, the stock could retest its 52-week low of $403.36, representing a 24.6% decline from the current price of $535.29. This scenario could be triggered by a sharp slowdown in organic growth, margin compression from inflation, or a broad market sell-off that compresses growth stock multiples. The analyst low target of $490 implies a more moderate 8.5% downside, but the historical max drawdown of 31.45% suggests deeper losses are possible in extreme conditions. An investor could lose up to 24.6% if the stock falls to the 52-week low.
